SPRC SciSparc Ltd
Price Chart
Executive Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs, has advanced its collaboration with Clearmind Medicine by publishing a PCT patent application for a novel MEAI-PEA combination therapy targeting obesity and MASLD. The press release highlights the potential of this non-hallucinogenic treatment as a safer, more cost-effective alternative to GLP-1 agonists, amid a rapidly growing global weight loss drug market.
Actionable Insight
Monitor for future clinical milestones, partnership developments, or additional IP filings; current announcement is speculative and preclinical, but could attract investor interest given the large target market.
Key Facts
- SciSparc holds ~75% ownership in NeuroThera Labs, which co-developed a patent-published combination therapy (MEAI-PEA) for obesity and MASLD.
- The therapy is positioned as a potential non-hallucinogenic, safer, and more cost-effective alternative to GLP-1 agonists.
- Global weight loss drug market was valued at $37B in 2025, projected to reach $226B by 2035.
- No clinical trial results, revenue, or funding details were disclosed — only patent publication and forward-looking statements.
Financial Impact
Potential long-term value if therapy advances clinically and commercially; no near-term financial impact due to early stage.
Risk Factors
- Therapy is in pre-patent publication stage with no clinical data yet — high development risk.
- Forward-looking statements dominate; actual outcomes may differ materially due to regulatory, clinical, or commercialization risks.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
6-K
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $9.31 (−19.32%) |
|
Jun 4, 2026
5d ago
|
Press Release
| $11.54 $11.44 | ▼ −0.87% | ▲ +1.73% | $9.31 (−19.32%) |
|
May 29, 2026
11d ago
|
6-K
| $9.81 $10.59 | ▲ +7.95% | ▲ +7.68% | $9.31 (−5.10%) |
|
May 28, 2026
12d ago
|
Press Release
| $10.55 $9.81 | ▼ −7.01% | ▼ −7.26% | $9.31 (−11.75%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $4.32 $4.62 | ▲ +6.94% | ▲ +6.67% | $9.31 (+115.51%) |
|
Mar 12, 2026
12w ago
|
Press Release
| $4.73 $4.36 | ▼ −7.82% | ▼ −7.22% | $9.31 (+96.83%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $4.02 $3.85 | ▼ −4.23% | ▼ −4.12% | $9.31 (+131.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access